PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
123.99%
ROE 1.25-1.5x AXSM's 104.99%. Bruce Berkowitz would see if management strategy leads to consistently higher returns.
-254.57%
Negative ROA while AXSM stands at 0.00%. John Neff would check for structural inefficiencies or mispriced assets.
30.73%
ROCE of 30.73% while AXSM is zero. Bruce Berkowitz would verify if partial profitability can be accelerated.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.